Gynaecological cancer in Australia
The following material has been sourced from the Australian Institute of Health and Welfare
Gynaecological cancer incorporates ICD-10 cancer codes C51 (Malignant neoplasm of vulva), C52 (Malignant neoplasm of vagina), C53 (Malignant neoplasm of cervix), C54 (Malignant neoplasm of corpus uteri), C55 (Malignant neoplasm of uterus, part unspecified), C56 (Malignant neoplasm of ovary), C57 (Malignant neoplasm of other and unspecified female genital organs) and C58 (Malignant neoplasm of placenta).
Estimated number of new cases of gynaecological cancer diagnosed in 2017
Estimated % of all new female cancer cases diagnosed in 2017
Estimated number of deaths from gynaecological cancer in 2017
Estimated % of all female deaths from cancer in 2017
Chance of surviving at least 5 years (2009–2013)
Females living with gynaecological cancer at the end of 2012 (diagnosed in the 5 year period 2008 to 2012)
New cases of gynaecological cancer
In 2013, there were 5,336 new cases of gynaecological cancer diagnosed in Australia. In 2017, it is estimated that 6,073 new cases of gynaecological cancer will be diagnosed in Australia.
In 2013, the age-standardised incidence rate was 40 new cases per 100,000 females. In 2017, it is estimated that the age-standardised incidence rate will be 42 cases per 100,000 females. The incidence rate for gynaecological cancer is expected to generally increase with age (Figure 1).
In 2017, it is estimated that the risk of a female being diagnosed with gynaecological cancer by her 85th birthday will be 1 in 21.
The number of new cases of gynaecological cancer diagnosed increased from 2,950 in 1982 to 5,336 in 2013. Over the same period, the age-standardised incidence rate decreased from 44 cases per 100,000 females in 1982 to 40 cases per 100,000 females in 2013 (Figure 2).
Deaths from gynaecological cancer
In 2014, there were 1,838 deaths from gynaecological cancer in Australia. In 2017, it is estimated that this will decrease to 1,769 deaths.
In 2014, the age-standardised mortality rate was 13 deaths per 100,000 females. In 2017, it is estimated that the age-standardised mortality rate will be 11 deaths per 100,000 females. The mortality rate for gynaecological cancer is expected to generally increase with age (Figure 1).
In 2017, it is estimated that the risk of a female dying from gynaecological cancer by her 85th birthday will be 1 in 66.
The number of deaths from gynaecological cancer increased from 1,120 in 1968 to 1,838 in 2014. Over the same period, the age-standardised mortality rate decreased from 23 deaths per 100,000 females in 1968 to 13 deaths per 100,000 females in 2014 (Figure 2).
Figure 1: Estimated age-specific incidence and mortality rates for gynaecological cancer, females, 2017
Source: AIHW analysis of the Australian Cancer Database and AIHW National Mortality Dataset (see source table 1).
Figure 2: Age-standardised incidence rates for gynaecological cancer 1982–2013 and age-standardised mortality rates for gynaecological cancer 1968–2014, females
Source: AIHW analysis of the Australian Cancer Database and AIHW National Mortality Dataset (see source table 2).
Survival from gynaecological cancer
In 2009–2013 in Australia, females diagnosed with gynaecological cancer had a 69% chance of surviving for 5 years compared to their counterparts in the general Australian population.
Between 1984–1988 and 2009–2013, 5-year relative survival from gynaecological cancer improved from 61% to 69%.
Figure 3: 5-year relative survival from gynaecological cancer, 1984–1988 to 2009–2013
Source: AIHW analysis of the Australian Cancer Database (see source table 3).
Prevalence of gynaecological cancer
The survivorship population is measured using prevalence data. Prevalence refers to the number of people alive who have previously been diagnosed with gynaecological cancer.
The prevalence for 1, 5 and 31 years given below are the number of people living with gynaecological cancer at the end of 2012 who had been diagnosed in the preceding 1, 5 and 31 years respectively.
At the end of 2012, there were 4,670 females living who had been diagnosed with gynaecological cancer that year, 18,469 females who had been diagnosed with gynaecological cancer in the previous 5 years (from 2008 to 2012) and 56,867 females who had been diagnosed with gynaecological cancer in the previous 31 years (from 1982 to 2012).
|Age group (years)||Incidence rate||Mortality rate|
|Year||Incidence rate||Mortality rate|
|Year||5-year relative survival (%)|
International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD–10)
Cancer is classified by the International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD–10). This is a statistical classification, published by the World Health Organization, in which each morbid condition is assigned a unique code according to established criteria.
Future estimations for incidence and mortality are a mathematical extrapolation of past trends. They assume that the most recent trends will continue into the future, and are intended to illustrate future changes that might reasonably be expected to occur if the stated assumptions continue to apply over the estimated period. Actual future cancer incidence and mortality rates may vary from these estimations. For instance, new screening programs may increase the detection of new cancer cases; new vaccination programs may decrease the risk of developing cancer; and improvements in treatment options may decrease mortality rates.
Cancer incidence indicates the number of new cancers diagnosed during a specified time period (usually one year).
The 2013 national incidence counts include estimates for NSW because the actual data were not available. Note that actual data for the Australian Capital Territory do not include cases identified from death certificates.
The 2017 estimates are based on 2004–13 incidence data. Due to rounding of these estimates, male and female incidence may not sum to person incidence.
Cancer mortality refers to the number of deaths occurring during a specified time period (usually one year) for which the underlying cause of death is cancer.
The 2017 estimates are based on mortality data up to 2013. Joinpoint analysis was used on the longest time series of age–standardised rates available to determine the starting year of the most recent trend.
Prevalence of cancer refers to the number of people alive with a prior diagnosis of cancer at a given time. It is distinct from incidence, which is the number of new cancers diagnosed within a given period of time. The longest period for which it is possible to calculate prevalence using the available national data (from 1982 to 2012) is currently 31 years so this is used to provide an estimate of the ‘total’ prevalence of cancer as at the end of 2012, noting that people diagnosed with cancer before 1982 aren’t included.
Age standardised rates
Incidence and mortality rates expressed per 100,000 population are age–standardised to the Australian population as at 30 June 2001.